US Pat. No. 10,138,520

DIAGNOSTIC MIRNA MARKERS FOR ALZHEIMER

SIEMENS AKTIENGESELLSCHAF...

1. A method of treating Alzheimer's Disease in a patient in need thereof, said method comprisingadministering an anti-Alzheimer's Disease therapy to the patient, wherein a blood sample from the patient exhibits an expression level value of at least one miRNA selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 56, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 78, SEQ ID NO 85, SEQ ID NO 142 and SEQ ID NO 236 compared to a reference expression level value.
US Pat. No. 10,138,264

RECOMBINED MOLECULES AND PREPARATION THEREOF

VALENT TECHNOLOGIES LLC, ...

1. A method for preparation of a recombined molecule from vancomycin comprising the steps of:(a) cleavage of vancomycin with a protease;
(b) splitting the cleaved vancomycin molecules into two separate pools: a first pool and a second pool;
(c) acylating the cleaved vancomycin molecules of the first pool with an acylating agent to acylate all alcohols and amino groups of the cleaved vancomycin molecules of the first pool;
(d) methylating the cleaved vancomycin molecules of the second pool with a methylating agent to methylate all carboxylic acid moieties of the cleaved vancomycin molecules of the second pool;
(e) recombining the acylated cleaved vancomycin molecules of the first pool and the methylated cleaved vancomycin molecules of the second pool by forming peptide bonds with a peptide bond forming agent to afford a recombined molecule from vancomycin comprising acetyl protecting groups and methyl protecting groups; and
(f) removing all acetyl protecting groups and all methyl protecting groups present in the recombined molecule from vancomycin in step (e) by base hydrolysis to produce a recombined molecule from vancomycin.
US Pat. No. 10,138,266

METHOD OF CUTTING OUT RNA OLIGONUCLEOTIDE

Nitto Denko Corporation, ...

1. A method of cutting out an RNA oligonucleotide chemically synthesized on a universal support from the support, comprisinga step of bringing the support carrying the RNA oligonucleotide in contact with an aqueous solution containing alkylamine and 10-60 mM monovalent inorganic salt.
US Pat. No. 10,138,523

CANCER BIOMARKER AND DIAGNOSTIC

1. A method for monitoring colorectal cancer in a subject, wherein the method comprises:(i) measuring the level of ATP11B and S100A11 gene expression or the quantity of protein or peptides resulting from ATP11B and S100A11 gene translation in samples from the subject from two or more successive time points;
(ii) comparing the level or quantity of both markers between the samples as measured in (i);
(iii) finding a deviation of at least about 40% (about 1.4-fold or more)_or no deviation of the quantity of both markers between the samples as compared in (ii); and
(iv) attributing the finding of deviation or no deviation to a change in the colorectal cancer in the subject between the two or more successive time points.
US Pat. No. 10,138,268

PEPTIDE FRAGMENT CONDENSATION AND CYCLISATION USING A SUBTILISIN VARIANT WITH IMPROVED SYNTHESIS OVER HYDROLYSIS RATIO

ENZYPEP B.V., Geleen (NL...

1. A method for enzymatically synthesizing an (oligo)peptide, comprising:coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine,
wherein the coupling is carried out in a fluid comprising water, and
wherein the coupling is catalyzed by a subtilisin BPN? variant or mutant, said variant or mutant comprising mutations, said mutations comprising:
a deletion of the calcium binding domain corresponding to amino acid corresponding to positions 75-83; and
a mutation at the amino acid position corresponding to S221, the mutation corresponding to S221C or S221selenocysteine;
wherein the amino acid positions are defined based upon the numbering of the amino acid sequence of SEQ ID NO:2, and wherein the subtilisin BPN? variant or mutant has enzymatic activity.
US Pat. No. 10,138,271

NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN

The United States of Amer...

1. A method of enhancing an immune response against a MUC1-expressing cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising(i) a poxvirus vector comprising a nucleic acid encoding a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32, or
(ii) a liposome comprising a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 29, and SEQ ID NO: 32,
wherein the immune response in the subject is enhanced.
US Pat. No. 10,138,016

COATED BOX WITH ANTI-GREASY FINGERPRINT COATING

FC Meyer Packaging LLC, ...

1. A container, comprising:a paperboard having creases that fold the paperboard into a box shape that has exterior facing surfaces that face away from each other and interior facing surfaces that face each other;
a water-based barrier coating on portions of the exterior facing surfaces of the paperboard to coat the portions and that is configured to prevent staining from grease and water of the portions of the exterior facing surfaces of the paperboard that are coated, the water-based barrier coating having 35% to 45% solid suspension and being configured to exhibit a hydrophobic effect to deposits of water and oil, the exterior facing surfaces also having uncoated portions that are uncoated and thereby lack the water-based barrier coating, the water-based barrier coating including a primer coat layer applied on the paperboard with the paperboard remaining open to absorb moisture even though the primer coat is applied on the paperboard, an overcoat layer on the primer coat layer and having a higher volume of a same coating material than that of the primer coat layer, the primer coat and the overcoat together providing a surface tension necessary to seal the paperboard against absorbing fluid and resist staining from greasy fingerprints; and
a water-based adhesive adhering the uncoated portions of the exterior facing surfaces to portions of the interior facing surfaces that are in alignment therewith.
US Pat. No. 10,141,607

NONAQUEOUS ELECTROLYTE SECONDARY BATTERY

GS Yuasa International Lt...

1. A nonaqueous electrolyte secondary battery comprising a nonaqueous electrolyte,wherein the nonaqueous electrolyte contains 2-fluorotoluene and lithium difluorophosphate,
the content of the 2-fluorotoluene is 4 mass % or more and 8 mass % or less per the nonaqueous electrolyte, and
the content of the lithium difluorophosphate is 1 mass % or more and 6 mass % or less per the nonaqueous electrolyte.
US Pat. No. 10,138,533

METHOD FOR PRODUCING HIGH-PURITY CALCIUM

1. High-purity calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of: less than 0.05 ppm, produced by a process comprising the steps of:charging calcium starting material having a purity, excluding the gas components, of 4N or less into a crucible of a sublimation vessel;
performing first sublimation purification by heating at 750° C. to 800° C. so that calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel;
recovering the calcium purified by the first sublimation purification;
charging the calcium into a crucible of a sublimation vessel again;
performing second sublimation purification by heating at 750° C. to 800° C. so that the calcium is sublimated and deposits (evaporates) onto the inner side wall of the sublimation vessel; and
recovering the calcium having a purity, excluding gas components, Sr, and Ba, of 4N5 or higher and containing silicon as an impurity in an amount of less than 0.05 ppm.
US Pat. No. 10,138,277

VIRUS-LIKE PARTICLES AND METHODS OF USE

The United States of Amer...

1. An isolated polynucleotide encoding an altered viral protein selected from the group consisting of:a. an alphavirus E2 protein comprising at least one alteration, relative to the wild-type amino acid sequence, at one or more amino acid locations corresponding to at least one amino acid position selected from the group consisting of H170, K200, K233, K234, R251, and H256 of Chikungunya E2 protein; and
b. an alphavirus capsid protein comprising at least one alteration, relative to the wild type sequence, in the Nuclear Localization Signal (NLS);
wherein the altered protein is capable of self-assembling into a virus like particle (VLP); and,
wherein the at least one alteration enhances production of VLPs.
US Pat. No. 10,138,534

NICKEL ALLOY

ROLLS-ROYCE plc, London ...

1. A nickel alloy having the following composition (in atomic percent unless otherwise stated): between 5.75 and 6.75 Al, between 4.5 and 5.8 Ti, between 0.5 and 1.3 Ta, up to 1% Nb, between 13.5% and 16% Cr, between 22and 27% Co, between 0.1 and 0.3% C, between 0.05 and 0.2% B, between 0.02 and 0.07% Zr, up to 1.1% W, between 1.4 and 2.85% Mo, up to 1% Fe, up to 0.7% Mn, up to 1% Si, up to 0.15% Hf, and up to 0.05% Mg; the balance being Ni and incidental impurities.
US Pat. No. 10,138,293

BIVALENT, BISPECIFIC ANTIBODIES

HOFFMANN-LA ROCHE, INC., ...

1. A bivalent, bispecific antibody comprising two pairs of light chains and heavy chains, each light chain comprising a variable region and a constant region, each heavy chain comprising a variable region and a constant region, wherein:a) the light chain and heavy chain of the first of the two pairs specifically bind to a first antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VL, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VH, CH1, CH2, CH3; and
b) the light chain and heavy chain of the second of the two pairs specifically bind to a second antigen, wherein the light chain comprises the following domains in N-terminal to C-terminal direction VH, CL and the heavy chain comprises the following domains in N-terminal to C-terminal direction VL, CH1, CH2, CH3.
US Pat. No. 10,138,038

ANTIMICROBIAL DETECTABLE CABLE TIE

1. A cable tie comprising:a body having a composition wherein the composition comprises a base plastic, an antimicrobial additive, and a detectable additive selected from a detectable metal additive, an X-ray detectable additive and combinations thereof, and wherein the antimicrobial additive includes silver ion complex and at least one selected from the group consisting of copper ion complex, polychloro phenoxy phenol derivative, quaternary ammonium compound, and zinc pyrithione derivative, and
a head having a barb comprising an antimicrobial metallic barb material,
wherein the body and the head are integrally connected, and wherein the antimicrobial metallic barb material comprises a copper alloy selected from the group consisting of C28000, C11000, C51000, C70600, C26000, and C75200.
US Pat. No. 10,139,320

COMPOSITION FOR PROCESSING HISTOLOGICAL, POSTMORTEM, CYTOLOGICAL SAMPLES

Giacomo Madau, Cagliari ...

1. A method to process a biological sample, the method comprisingtreating the biological sample with a composition to process the biological sample, the composition comprising
at least one 2-ethylhexyl ester selected from the group consisting of 2-ethylhexyl benzoate, 2-ethylhexyl palmitate, 2-ethylhexyl cocoate, 2-ethylhexyl stearate, and 2-ethylhexyl acetate; and
ethyl alcohol and/or isopropyl alcohol,
wherein the at least one 2-ethylhexyl ester is in a concentration ranging from 30% to 70%, with respect to a total volume of the composition, the ethyl alcohol is in a concentration ranging from 20% to 60% with respect to the total volume of the composition and the isopropyl alcohol is in a concentration ranging from 10% to 30% with respect to the total volume of the composition.
US Pat. No. 10,139,321

MUCOLYTIC TABLET FOR A SAMPLE COLLECTION DEVICE

Alpha-Tec Systems, Inc., ...

1. A mucolytic tablet for a sample collection device, comprising:(i) 15% to 65% by weight of N-acetyl L-cysteine (NALC);
(ii) 6% to 30% by weight of a buffering agent;
(iii) 10% to 14% by weight of a water soluble anti-adherent; and
(iv) 2% to 10% by weight of at least one water soluble chelating and lubricating agent,
wherein the mucolytic tablet solubilizes in a resuspension buffer.
US Pat. No. 10,138,299

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Bristol-Myers Squibb Comp...

1. A method of treating a tumor in a human subject in need thereof, comprising administering to the subject about 10 mg/kg of an anti-PD-L1 antibody every 2 weeks, wherein the anti-PD-L1 antibody is administered intravenously over 60 minutes infusion;wherein the tumor is derived from a bladder cancer of; and wherein the tumor is refractory to a platinum based chemotherapy.
US Pat. No. 10,138,300

ANTI-VEGFR ANTIBODY AND USES THEREOF

DEVELOPMENT CENTER FOR BI...

1. An antibody or antigen-binding fragment thereof that specifically binds to an epitope in human vascular endothelial growth factor receptor 2 (VEGFR-2) or a fragment thereof; wherein the human vascular endothelial growth factor receptor 2 has the amino acid sequence of SEQ ID NO: 1, and the epitope comprises:the serine residue at position 711, the lysine residue at position 716, the aspartic acid residue at position 717, and the arginine residues at positions 725 and 726 of SEQ ID NO: 1; which antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region and complementarity determining regions of a light chain variable region, wherein the complementarity determining regions of the heavy chain variable region comprises CDRH1, CDRH2 and CDRH3 regions, and the complementarity determining regions of the light chain variable region comprises CDRL1, CDRL2 and CDRL3 regions, and the CDRH1 region comprises the amino acid sequence of SEQ ID NO: 4; the CDRH2 region comprises the amino acid sequence of SEQ ID NO: 5; the CDRH3 region comprises the amino acid sequence of SEQ ID NO: 6; the CDRL1 region comprises the amino acid sequence of SEQ ID NO: 7; the CDRL2 region comprises the amino acid sequence of SEQ ID NO: 8; and the CDRL3 region comprises the amino acid sequence of SEQ ID NO: 9.
US Pat. No. 10,138,301

MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2

GALAXY BIOTECH, LLC, Cup...

1. An isolated monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2 IIIb) comprising a light chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO. 1 and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4.
US Pat. No. 10,138,558

PRETREATMENT AGENT FOR ELECTROLESS PLATING, AND PRETREATMENT AND PRODUCTION OF PRINTED WIRING BOARD USING SAME

1. A pretreatment agent for electroless plating, comprising:a silane coupling agent;
a surfactant; and
ethylene-based glycol butyl ethers of formula: C4H9—(OC2H4)nOH where n is an integer of 1 to 4, and/or propylene-based glycol butyl ethers of formula: C4H9—(OC3H6)nOH where n is an integer of 1 to 4.
US Pat. No. 10,138,560

METHODS AND SYSTEMS UTILIZING A BORON-CONTAINING CORROSION INHIBITOR FOR PROTECTION OF TITANIUM SURFACES

Halliburton Energy Servic...

1. A method comprising:contacting a metal surface consisting of titanium or a titanium alloy with a corrosion inhibitor composition comprising a boron-containing compound, wherein the boron-containing compound comprises a boron-alkanolamine complex;
interacting the metal surface with a fluid phase comprising hydrofluoric acid or acidic fluoride ions; and
suppressing corrosion of the metal surface by the hydrofluoric acid or acidic fluoride ions with the boron-containing compound.
US Pat. No. 10,138,304

METHODS FOR INCREASING THE EXTRACTABLE RUBBER CONTENT OF NON-HEVEA PLANT MATTER

Bridgestone Corporation, ...

1. A method for increasing the extractable rubber content of non-Hevea plant matter without unduly increasing the extractable resin content comprising:utilizing a quantity of chopped non-Hevea plant matter having an average length of ½? to 4? and a maximum moisture content of 15 weight % and subjecting the chopped non-Hevea plant matter to at least one of
hammer milling utilizing a screen size of less than ½? and greater than or equal to 3/16?; and
roller milling with corrugated rolls having no more than 8 corrugations per inch,
thereby producing a quantity of milled non-Hevea plant matter having a maximum moisture content of 15 weight %, an extractable rubber content at least 30% higher than the pre-milled chopped non-Hevea plant matter and an extractable resin content of no more than 3 times the extractable rubber content.
US Pat. No. 10,138,308

CATALYST COMPONENT FOR THE PREPARATION OF NUCLEATED POLYOLEFINS

BOREALIS AG, (AT)

1. A process of obtaining a catalyst composition containing a catalyst component, the process comprising:a1) providing a solution of at least a Group 2 metal alkoxy compound (Ax) being the reaction product of a Group 2 metal compound (MC) and a monohydric alcohol (A) comprising in addition to the hydroxyl moiety at least one ether moiety optionally in an organic liquid reaction medium; or
a2) providing a solution of at least a Group 2 metal alkoxy compound (Ax?) being the reaction product of a Group 2 metal compound (MC) and an alcohol mixture of the monohydric alcohol (A) and a monohydric alcohol (B) of formula ROH, optionally in an organic liquid reaction medium; or
a3) providing a solution of a mixture of the Group 2 metal alkoxy compound (Ax) and a Group 2 metal alkoxy compound (Bx) being the reaction product of a Group 2 metal compound (MC) and the monohydric alcohol (B), optionally in an organic liquid reaction medium; or
a4) providing a solution of Group 2 metal alkoxy compound of formula M(OR1)n(OR2)mX2-n-m or mixture of Group 2 alkoxides M(OR1)n?X2-n? and M(OR2)m?X2-m?, where M is Group 2 metal, X is halogen, R1 and R2 are different alkyl groups of C2 to C16 carbon atoms, and 0 b) adding said solution from step a) to at least one compound (TC) of a transition metal of Group 4 to 6, and
c) obtaining the solid catalyst component particles,
d) washing said solidified particles,
e) recovering the solidified particles of the olefin polymerisation catalyst component, wherein an electron donor is added at any step prior to step c) and is a non-phthalic internal electron donor, and
wherein the catalyst component is further modified by a polymeric nucleating agent comprising vinyl compound units;
wherein the catalyst component is washed in step d) at least three times with at least one toluene and at least one TiCl4 washing step and 1 to 3 further washing steps with an aromatic and/or aliphatic hydrocarbon selected from toluene, heptane or pentane; and
wherein internal donor is added to either the toluene wash step and/or to the TiCl4 wash step, whereby the amount of donor added to the washing steps is in the range of 10 to 60 wt % of the total amount of donor used in catalyst preparation steps a) to d).
US Pat. No. 10,138,569

WELD CLEANING FLUID

Ensitech IP PTY LLP, Emu...

1. A stainless steel cleaning composition, comprising:an aqueous solution having a pH that is approximately neutral, said aqueous solution having from more than 30% to 60% by weight of a phosphoric acid salt, and having up to 20% by weight of a salt of a polyaminocarboxylic acid as a sequestering or chelating agent,
wherein said acid salt is selected to induce passivation of stainless steel through oxidation of chromium atoms within the stainless steel, and
all optional components of said composition are selected to be chemically unreactive with, and non-chemically-bonding to, metals.
US Pat. No. 10,138,314

RUBBER GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING RUBBER GRAFT COPOLYMER

KANEKA CORPORATION, Osak...

1. A rubber graft copolymer comprising a core layer containing a rubber polymer and a shell layer grafted on the core layer satisfying all of the following (1) to (7):(1) the rubber graft copolymer polymerized under the presence of an alkaline metal salt of a phosphate compound,
(2) the rubber graft copolymer obtained by contacting a solution containing an alkaline earth metal chloride to a latex containing the rubber graft copolymer obtained by the emulsion polymerization to coagulate the copolymer,
(3) the rubber graft copolymer in which the phosphate compound remains as an alkaline earth metal salt in the rubber graft copolymer, the remaining amount of the alkaline earth metal salt of the phosphate compound is 400 ppm or more and 3000 ppm or less as an alkaline earth metal on a mass basis,
(4) the rubber graft copolymer obtained by polymerizing at conditions of pH of 5.0 to 9.0,
(5) the rubber graft copolymer in which the rubber polymer is a polybutadiene or a poly (butadiene-styrene),
(6) a concentration of monomers used in the polymerization of the shell layer is (i) 60 to 80% by mass of methyl methacrylate and 20 to 40% by mass of styrene, or (ii) 70 to 99% by mass of methyl methacrylate and 1 to 30% by mass of butylacrylate, or (iii) 30 to 40% by mass of glycidyl methacrylate, 45 to 55% by mass of methylmethacrylate, and 5 to 25% by mass of styrene, per 100% by mass of monomers constituting the shell layer, and
(7) the alkaline metal salt of the phosphate compound is polyoxyalkylene alkyl phenyl ether phosphate salt or polyoxyalkylene alkyl ether phosphate salt.
US Pat. No. 10,138,316

AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS

Novartis AG, Basel (CH)

1. An amphiphilic branched polydiorganosiloxane macromer, comprising:(1) at least first one polydiorganosiloxane polymer chain having two terminal methacryloyl groups; and
(2) at least one first hydrophilic chain;
(3) at least one second hydrophilic polymer chain; and
(4) at least one second polydiorganosiloxane polymer chain at least one end of which is covalently connected to the second hydrophilic polymer chain,
wherein the first and second polydiorganosiloxane chains are derived from an ?,?-dimethacryloyl-terminated polydiorganosiloxane vinylic crosslinker comprising one or more ATRP-containing siloxane units having one substituent having an ATRP initiator,
wherein the first hydrophilic chain is anchored covalently onto one single ATRP-containing siloxane unit of the first or second polydiorganosiloxane chain at one of the two ends of the first hydrophilic polymer chain and has one first terminal group at the other one of the two ends of the first hydrophilic polymer chain,
wherein the second hydrophilic polymer chain is (a) anchored covalently onto one single ATRP-containing siloxane unit of the first polydiorganosiloxane chain at one of the two ends of the second hydrophilic polymer chain, (b) has one second terminal group at the other one of the two ends of the second hydrophilic polymer chain, and (c) is covalently connected to covalently connected to one of the two ends of the second polydiorganosiloxane chain,
wherein the first and second terminal groups independent of each other are (meth)acryloxy group, (meth)acryloxy-C2-C4 alkoxy group, (meth)acrylamido-C2-C4 alkoxy group, (meth)acryloxy-C2-C4 alkylamino group, (meth)acrylamido-C2-C4 alkylamino group, C1-C6 substituted or unsubstituted alkoxy group, C2-C6 substituted or unsubstituted alkanoyloxy group, or C1-C6 substituted or unsubstituted alkylamino group, wherein the first and second hydrophilic polymer chains are composed of monomeric units of at least one hydrophilic vinylic monomer selected from the group consisting of (meth)acrylamide, N,N-dimethyl (meth)acrylamide, dimethylaminoethyl (meth)acrylate, dimethylaminoethyl (meth)acrylamide, N-vinyl-2-pyrrolidone, N-vinyl-N-methyl isopropylamide, N-vinyl-N-methyl acetamide, N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-methyl acetamide, hydroxyethyl (meth)acrylate, hydroxyethyl (meth)acrylamide, hydroxypropyl (meth)acrylamide, glycerol methacrylate (GMA), polyethylene glycol (meth)acrylate, polyethylene glycol C1-C4-alkyl ether (meth)acrylate having a number average molecular weight of up to 1500, and mixtures thereof.
US Pat. No. 10,138,576

BIOCOMPATIBLE HYDROPHILIC COMPOSITIONS

3M INNOVATIVE PROPERTIES ...

1. A nonwoven web of fibers, wherein the fibers comprise a blend comprising:at least one thermoplastic aliphatic polyester;
an alkyl, alkenyl, aralkyl, or alkaryl anionic surfactant incorporated in the polyester; wherein the surfactant is selected from the group consisting of alkyl sulfate, alkenyl sulfate, alkaryl sulfate, aralkyl sulfate, alkylalkoxylated sulfate, alkyl sulfonate, alkenyl sulfonate, alkaryl sulfonate, aralkyl sulfonate, alkylalkoxylated sulfonate, alkyl phosphonate, alkenyl phosphonate, alkaryl phosphonate, aralkyl phosphonate, alkyl phosphate, alkenyl phosphate, alkaryl phosphate, aralkyl phosphate, alkyl alkoxylated phosphate, di(C8-C18) sulfosuccinate salts, C8-C22 alkyl sarcosinate salts, C8-C22 alkyl lactylate salts, and combinations thereof; wherein the surfactant is present in a concentration sufficient to make the nonwoven web durably hydrophilic and absorbent and instantaneously wettable; and
a surfactant carrier;
wherein the fibers are 20 micrometers or less in diameter;
wherein the surfactant is soluble in the carrier at greater than 10% by weight such that the surfactant and carrier form a visually transparent solution in a 1-cm path length glass vial when heated to 150° C.
US Pat. No. 10,138,577

POLYPHENYLENE SULFIDE FIBERS, AND MANUFACTURING METHOD THEREFOR

Toray Industries, Inc., ...

1. A poly(phenylene sulfide) fiber containing 1-10% by weight of a poly(phenylene sulfide) oligomer having a weight-average molecular weight of 5,000 or less, having a difference between a cold crystallization heat quantity (?Hc) and a crystal melting heat quantity (?Hm) during temperature rising in DSC, ?Hm??Hc, of 25 J/g or larger, and having an elongation of less than 40% and a strength of 3.0 cN/dtex or higher.
US Pat. No. 10,138,321

PROCESS FOR PRODUCTION OF OXYMETHYLENE COPOLYMER

MITSUBISHI GAS CHEMICAL C...

1. A method for producing an oxymethylene copolymer, comprising a polymerization step for cationically polymerizing trioxane and a comonomer at a polymerization temperature of from 135 to 300° C. in the presence of at least one salt of a protonic acid having a molecular weight of 1,000 or less, and at least one polymerization initiator selected from the group consisting of protonic acids having a molecular weight of 1,000 or less, protonic acid anhydrides having a molecular weight of 1,000 or less, and protonic acid ester compounds having a molecular weight of 1,000 or less, wherein the trioxane and comonomer used in the polymerization step contain metal components in a total concentration of 300 ppb by mass or less.
US Pat. No. 10,138,326

METHOD OF PRODUCING COPOLYESTER MATERIAL WITH PEPTIDE AND COPOLYESTER MATERIAL WITH PEPTIDE THEREOF

Camangi Corporation, Tai...

1. A method of producing copolyester material with peptide, comprising:putting ethylene glycol (EG), collagen peptide, and benzenedicarboxylic acid into a container, and mixing the ethylene glycol, the collagen peptide, and the benzenedicarboxylic acid to form a mixture, wherein in the mixture, a molar ratio of the collagen peptide, the ethylene glycol, and the benzenedicarboxylic acid is (0.47-0.60): (0.90-1.10): (1.14-1.26); heating the mixture for executing an esterification reaction, to produce esters and water;
heating the esters to a first temperature, and stirring the esters via a mixer;
in a specific period, decreasing a pressure in the container to a first pressure for executing a polycondensation reaction; and
decreasing the pressure in the container to a second pressure, and stirring the esters via the mixer, to produce a copolyester material with peptide.
US Pat. No. 10,138,328

METHOD FOR PRODUCING POLYETHER CARBONATE POLYOLS

Covestro Deutschland AG, ...

1. A process for preparing polyether carbonate polyols, comprising reacting alkylene oxide with carbon dioxide in the presence of an H-functional starter compound and double metal cyanide catalyst, wherein the process comprises:(?) optionally, pretreating a double metal cyanide catalyst (DMC catalyst) at a temperature of 50 to 200° C. and/or reduced pressure (absolute) of 10 mbar to 800 mbar in a first reactor,
(?) contacting the double metal cyanide catalyst and suspension medium with alkylene oxide to obtain a first reaction mixture in a first reactor;
and
(?) continuously adding the first reaction mixture, alkylene oxide, carbon dioxide and optionally H-functional starter compound to a second reactor,
wherein at least one H-functional starter compound is added at least in one of steps (?) and (?) and
wherein reaction products formed in step (?) are withdrawn continuously from the second reactor.
US Pat. No. 10,138,330

SILICONE ELASTOMERS CAPABLE OF LARGE ISOTROPIC DIMENSIONAL CHANGE

Lawrence Livermore Nation...

1. A method for making a microfluidic device, comprising forming a microfluidic pattern comprising at least one line having a width of 500 ?m or less with a silicone-based elastomer, wherein the silicone-based elastomer comprises a network of crosslinked polysiloxane having its internal space occupied by a guest molecule, and removing the guest molecule from the silicone-based elastomer to isotropically reduced the volume of the silicone-based elastomer by at least 20%.
US Pat. No. 10,138,593

SIZING AGENT-COATED CARBON FIBERS, PROCESS FOR PRODUCING SIZING AGENT-COATED CARBON FIBERS, PREPREG, AND CARBON FIBER REINFORCED COMPOSITE MATERIAL

Toray Industries, Inc., ...

1. Sizing agent-coated carbon fibers comprising:a sizing agent coating that includes:
an aliphatic epoxy compound (A) that has three or more epoxy groups and at least one hydroxy group in a molecule,
an aromatic epoxy compound (B1) as a type of aromatic compound (B), and
an aromatic ester compound (C1); and
carbon fibers coated with the sizing agent,whereinthe sizing agent contains the aliphatic epoxy compound (A) in an amount of 35 to 65% by mass relative to the total amount of the sizing agent exclusive of solvent;
the sizing agent contains the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) in a mass ratio (A)/(B1) of 52/48 to 80/20;
the sizing agent contains the aromatic ester compound (C1) in an amount of 2 to 35% by mass relative to the total amount of the sizing agent exclusive of solvent;
each of the aliphatic epoxy compound (A) and the aromatic epoxy compound (B1) has a surface tension of 35 to 45 mJ/m2 at 125° C.;
the sizing agent-coated carbon fibers have an (a)/(b) ratio of 0.50 to 0.90, wherein (a) is a height (cps) of a component at a binding energy (284.6 eV) assigned to CHx, C—C, and C?C and (b) is a height (cps) of a component at a binding energy (286.1 eV) assigned to C—C in a C1s core spectrum of a surface of the sizing agent applied onto the carbon fibers analyzed by X-ray photoelectron spectroscopy using AlK?1,2 as an X-ray source at a photoelectron takeoff angle of 15°; and
the carbon fibers have a surface carboxy group concentration COOH/C of 0.003 to 0.015 and a surface hydroxy group concentration COH/C of 0.001 to 0.050 determined by chemical modification X-ray photoelectron spectroscopy.
US Pat. No. 10,137,168

VETERINARY DECORIN COMPOSITIONS AND USE THEREOF

CATALENT PHARMA SOLUTIONS...

1. A veterinary decorin core protein molecule that is at least 98% identical to one of SEQ ID NOs:4, 7, 10, 13, 16, 19, 22, and 27, wherein the veterinary core protein molecule comprises an aspartic acid residue at the N-terminus and does not comprise a serine residue at the fourth amino acid from the N-terminus.
US Pat. No. 10,137,169

COMPOSITIONS AND USES THEREOF

Follicum AB, Lund (SE)

1. A composition for stimulating hair growth in a mammal comprising:(a) a modified osteopontin polypeptide in which an RGD domain is inactivated; and
(b) a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent,wherein the modified polypeptide comprises the amino acid sequence of SEQ ID NO: 63.
US Pat. No. 10,137,425

METHODS AND DEVICES BASED UPON A NOVEL FORM OF NUCLEIC ACID DUPLEX ON A SURFACE

Genomics USA, Inc., Roun...

1. A biomolecular hybridization device comprising:a substrate having a surface of functional groups permanently and covalently attached thereto;
an adsorbed monolayer of unmodified, single-stranded oligonucleotides each of which are 10 to about 24 bases in length as a saturated film of constrained oligonucleotides on the surface via direct non-covalent phosphate-surface adsorptive contact of substantially all phosphate groups of each oligonucleotide; wherein each constrained oligonucleotide base plane is presented from the surface in a manner effective to dissociably hybridize to a complementary single-stranded nucleic acid with asymmetric, non-helical base pairing without alteration of the oligonucleotide base plane presentation and without oligonucleotide phosphate group dissociation from the surface; wherein the hybridized oligonucleotides are fixed into an asymmetric, non-helical duplex;andpoly-T sequence at one or both of the 5? or 3? end of the oligonucleotides such that the adsorbed oligonucleotides including poly-T sequence(s) are each about 30 bases in length.
US Pat. No. 10,137,171

METHODS OF TREATMENT USING A PENTAPEPTIDE DERIVED FROM THE C-TERMINUS OF GLUCAGON-LIKE PEPTIDE 1 (GLP-1)

The General Hospital Corp...

wherein Xaa can be Gly, Gly-Arg, Gly-Arg-Gly, or absent,and a physiologically acceptable carrier, to a subject in need thereof.
US Pat. No. 10,137,172

ADMINISTRATION REGIME

1. An insulin titration method comprising:(a) obtaining a fasting blood or plasma sample, or non-invasive glucose measurement from an individual in need of treatment of type 2 diabetes;
(b) performing a single fasting blood or plasma glucose measurement on the sample obtained in (a);
(c) using the single fasting blood or plasma glucose measurement obtained in (b) to determine a LysB29(N?-hexadecandioyl-?-Glu) des(B30) human insulin (insulin degludec) dose to be administered; and
(d) administering said insulin to the individual at the dose determined in step (c);wherein subsequent doses of insulin are titrated by repeating step (a) and (b), the measurement being:?3.9 mmol/L (?70 mg/dL): the dose administered in step (d) is reduced by 4 U compared to the dose previously administered; or
4 to 5 mmol/L (71 to 90 mg/dL): the dose administered in step (d) is unaltered compared to the dose previously administered; or
?5.1 mmol/L (?91 mg/dL): the dose administered in step (d) is increased by 4 U compared to the dose previously administered;wherein step (d) is performed for an administration period of at least 3 days between two consecutive titrations; andwherein comparable improvements in HbA1c levels are seen relative to titration methods that are based on an average of at least three consecutive fasting blood glucose measurements per week.
US Pat. No. 10,138,196

PROCESS FOR PREPARING AN UNSATURATED CARBOXYLIC ACID SALT

BASF SE, Ludwigshafen (D...

1. A catalytic process for preparing an ?, ?-ethylenically unsaturated carboxylic acid salt, the process comprising:a) contacting an alkene and carbon dioxide with a carboxylation catalyst and an alkoxide, the alkoxide having a secondary or tertiary carbon atom directly bound to a [O?] group, to obtain a crude reaction product comprising the ?,?-ethylenically unsaturated carboxylic acid salt and an alcohol byproduct which is a conjugate acid of the alkoxide,
b) contacting at least part of the crude reaction product with a polar solvent such that a first liquid phase in which the ?,?-ethylenically unsaturated carboxylic acid salt is enriched, and a second liquid phase in which the carboxylation catalyst is enriched, are obtained, and
c) distilling an alcohol byproduct off from the first liquid phase.
US Pat. No. 10,137,173

ANTIVIRAL ACTIVITY OF GAS6 INHIBITOR

Aravive Biologics, Inc., ...

1. A method of inhibiting entry of an enveloped virus that expresses or incorporates phosphatidylserine in its outer membrane, into a cell, the method comprising:administering a soluble AXL variant polypeptide in a dose effective to inhibit the interaction between phosphatidylserine present at the outer membrane of the virus and of GAS6, wherein the virus is a filovirus, a lentivirus, a poxvirus, or a herpesvirus; and wherein said soluble AXL variant polypeptide lacks the AXL transmembrane domain and comprises amino acid modifications selected from the group consisting of:
(i) Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg; and
(ii) Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg.
US Pat. No. 10,138,197

DIRECT CATALYTIC PARTIAL OXIDATION OF ALLYL ETHER

EXXONMOBIL RESEARCH AND E...

1. A process for forming allyl acrylate, comprising contacting allyl ether with a solvent, wherein the solvent is selected from acetonitrile, chloroform, dichloromethane, N,N-dimethylformamide, N,N-dimethyl acetamide, dimethyl sulfoxide, or dimethylcarbonate, and with an oxidant, wherein the oxidant is selected from oxygen, oxygen-containing gases, peroxides, and mixtures thereof in the presence of a mesoporous manganese oxide (MnOx) catalyst.
US Pat. No. 10,137,174

METHODS AND MATERIALS FOR TREATING CANCERS THAT EXPRESS REDUCED LEVELS OF WILD-TYPE P53 POLYPEPTIDES

Mayo Foundation for Medic...

1. A method for treating cancer in a mammal, wherein said method comprises:(a) identifying a mammal as having cancer cells that express a reduced level of wild-type p53 polypeptides, and
(b) administering, to said mammal, a USP10 polypeptide or composition that increases USP10 polypeptide expression or activity within said cancer cells and increases wild-type p53 polypeptide expression with said cancer cells, thereby reducing cancer cell proliferation within said mammal.
US Pat. No. 10,138,199

HIGH ASPECT RATIO LAYERED DOUBLE HYDROXIDE MATERIALS AND METHODS FOR PREPARATION THEREOF

Saudi Arabian Oil Company...

1. A method for preparing adamantane-intercalated layered double-hydroxide (LDH) particles, the method comprising:adding to an aqueous solution a first precursor and a second precursor to form an initial mixture, where:
the first precursor is Al(OH)3 or Al2O3;
the second precursor is a hydroxide M(OH)2 or an oxide MO, where M is a metal of oxidation state +2; and
the initial mixture has a M/AI molar ratio from 1 to 5;
the initial mixture has a solid loading of less than 10 weight % solids, based on a total weight of the initial mixture;
adding to the initial mixture an amount of adamantane to form a reaction mixture having an Al/adamantane molar ratio from 0.5 to 2; and
heating the reaction mixture to produce the adamantane-intercalated LDH particles, where the adamantane-intercalated LDH particles have an aspect ratio greater than 100, the aspect ratio defined by a width of an adamantane-intercalated LDH particle divided by a thickness of the adamantane-intercalated LDH particle.
US Pat. No. 10,137,176

COMPOSITIONS AND METHODS FOR TREATING MPSI

The Trustee of the Univer...

1. A recombinant adeno-associated virus (rAAV) particle having an AAV capsid and having packaged therein a 5? inverted terminal repeat (ITR), a human alpha-L-iduronidase (hIDUA) gene under the control of regulatory sequences which control expression thereof, and an AAV 3? ITR, wherein said hIDUA gene has a sequence of SEQ ID NO: 1 or a sequence at least about 95% identical to SEQ ID NO: 1 which encodes a functional human alpha-L-iduronidase.
US Pat. No. 10,136,666

DEEP EUTECTIC SOLVENTS AND FLAVOUR GENERATION

Nestec S.A., Vevey (CH)

1. A process for the preparation of a flavor composition comprising the steps:forming a deep eutectic solvent;
preparing a reaction mixture comprising the deep eutectic solvent and flavor precursors selected from the group consisting of amino acids and peptides; and heating the reaction mixture to form aroma compounds, wherein the deep eutectic solvent is a liquid comprising a combination of at least two compounds solid at 25° C. and comprises water and/or glycerol in an amount insufficient to dissolve all the compounds solid at 25° C. individually, or in an amount such that all the compounds solid at 25° C. are simultaneously saturated at 25° C., wherein the flavor precursors comprise the compounds solid at 25° C., and wherein the at least two compounds solid at 25° C. are selected from the group consisting of: amino acids; organic acids having 6 carbons or fewer; monosaccharides or disaccharides; sugar alcohols having 12 carbons or fewer; choline chloride; betaine; carnitine; edible salts of sodium, potassium, magnesium or calcium; ribonucleotides; and urea; with the proviso that the two compounds are not both edible salts of sodium, potassium, magnesium or calcium; or are not both ribonucleotides.
US Pat. No. 10,137,178

DENTAL GEL COMPOSITION OF PAPAIN FOR THE ATRAUMATIC TREATMENT OF CARIES AND METHOD OF PREPARING SAME

BRIX USA, LLC, Newark, D...

1. A dental composition of papain in the form of a gel for the atraumatic treatment of caries comprising papain with a final activity of at least 3,000 U/mg, wherein the papain is bio-encapsulated in a mixture comprising all of the following ingredients:pH=7 buffer,
a C3-6 polyol,
pectin,
C2-6 alkanolamine,
a nonionic emulsifier,
optionally a pharmaceutically acceptable coloring agent
a preservative, and
a solvent,
wherein the composition does not include chloramine.
US Pat. No. 10,138,460

DEVICES, SYSTEMS AND METHODS FOR THE PRODUCTION OF HUMANIZED GUT COMMENSAL MICROBIOTA

1. A method for ex vivo production of human gut microbiota, comprising:screening a first sample of gut microbiota obtained from a first human subject to detect or remove ova, parasites, or viruses;
immobilizing the screened gut microbiota on a growth template coated with human cells, tissue extracts, adhesive proteins, or commensal colonizing factors;
seeding a synthetic, ex vivo culture medium with the immobilized sample;
adding nutrients to the synthetic culture medium to produce both cultured aerobic and anaerobic gut microbiota;
maintaining the temperature and gas gradients of the culture medium so as to be similar to the human gut; and
harvesting the cultured gut microbiota.
US Pat. No. 10,139,744

ELECTROSTATIC LATENT IMAGE DEVELOPING TONER

KYOCERA Document Solution...

8. An electrostatic latent image developing toner comprising toner particles each including a toner core and a shell layer covering a surface of the toner core, whereinthe shell layer contains a hydrophilic thermosetting resin and a hydrophobic thermoplastic resin,
the hydrophilic thermosetting resin is a resin having at least one functional group selected from the group consisting of oxazoline groups, carbodiimide groups, and isocyanate groups,
the hydrophobic thermoplastic resin is exposed at surfaces of the toner particles, and
the hydrophilic thermosetting resin is a polymer of a monomer containing at least one compound selected from the group consisting of 2-isopropenyl-2-oxazoline, 2-(penta-4-ynyl)-2-oxazoline, 2-isocyanatoethyl acrylate, and 2-isocyanatoethyl methacrylate.
US Pat. No. 10,137,180

METHODS FOR REGULATING PROTEIN FUNCTION IN CELLS IN VIVO USING SYNTHETIC SMALL MOLECULES

THE BOARD OF TRUSTEES OF ...

1. An in vivo method for increasing the stability of IL-2 or TNF-? in a mammal comprising:(a) introducing into one or more mammalian cells in vitro, a nucleic acid comprising a polynucleotide encoding a fusion protein, wherein the fusion protein comprises in an N-terminal to C-terminal direction:
i) a signal peptide, wherein the signal peptide facilitates secretion of the fusion protein,
(ii) a single-polypeptide chain, ligand-dependent, stability-affecting FKBP variant protein, comprising F36V and L106P amino acid substitutions fused to the signal peptide, and
(iii) IL-2 or TNF-? fused to the stability-affecting FKBP variant protein,
wherein said introducing generates one or more transformed mammalian cells expressing and secreting the fusion protein;
(b) implanting the one or more transformed cells from (a) into a mammal harboring a tumor, and
(c) administering a Shield1 ligand to the mammal from (b), wherein the Shield1 ligand binds to the stability-affecting FKBP variant protein and said binding increases stability of IL-2 or TNF-? by reducing degradation of the fusion protein, increases regulatory T-cell infiltration into tumor cells, and increases the survival rate of the mammal when compared to the same species of mammal constitutively expressing IL-2 or TNF-?.
US Pat. No. 10,138,204

METHOD FOR PRODUCING N-RETINOYLCYSTEIC ACID ALKYL ESTER

ARDENIA INVESTMENTS, LTD,...

1. A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providingi) a first solution comprising an aminoalkane sulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, an alcohol selected from aliphatic alcohols comprising 1 to 4 carbon atoms and a first base selected from trialkylamines,
ii) a second solution comprising a retinoic acid, a chloroformate, an aprotic solvent and a second base,
adding first and second solutions in any order to a reaction vessel thereby forming a reaction mixture comprising at least a liquid phase being one phase, mixing said reaction mixture, wherein retinoic acid, aminoalkane sulfonic acid and chloroformate are all soluble and present in said liquid phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase under conditions characterised as being substantially free from oxidizing compounds.
US Pat. No. 10,137,181

ISOLATED DONOR MHC-DERIVED PEPTIDE AND USES THEREOF


US Pat. No. 10,137,437

METHOD FOR PRODUCING A CATALYST FOR THE PARTIAL OXIDATION/AMMOXIDATION OF OLEFINS

Clariant Corpoation, Lou...

1. A method for producing a catalyst which includes as the catalytically active component a compound having the general formula MoxBiyFezAaBbCcDdOv, where A stands for Ni and/or Co, B stands for one or more metals selected from Mg, Cr, Mn, Zn, Ce, and Ca and combinations thereof, C stands for W, and D stands for one or more alkali metals, where x stands for a number from 10 to 14, y stands for a number from 0.1 to 5, z stands for a number from 0.5 to 5, a stands for a number from 1 to 10, b stands for a number from 0.1 to 6, c stands for a number from ?0 to 2, d stands for a number from 0.02 to 2, and v is determined by the oxidation state of the elements, the method including the following steps:a) providing a solution in which all precursor compounds of the Mo, Bi, Fe, A, B, C and D components of the catalytically active component are essentially completely dissolved in a suitable solvent;
b) bringing the solution obtained in step a) into contact with a chemically inert, porous support having a specific surface of 1 to 500 m2/g; and
c) heat treatment of the material obtained in step b), in which the precursor compounds of the catalytically active component are converted to their oxides.
US Pat. No. 10,137,182

CANCER VACCINES AND VACCINATION METHODS

Immunocellular Therapeuti...

1. A composition comprising a pharmaceutically acceptable carrier, an adjuvant, and a mixture of at least one major histocompatibility complex (MHC) class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen variant having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 19-25 and at least one MHC class I peptide epitope of 8-10 amino acids in length derived from each of at least six different antigens or variants thereof selected from the group consisting of:a mesothelin antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-18;
an NY-ESO-1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 27;
an FBP antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 28 and SEQ ID NO: 29;
a HER-2/neu antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 30-48;
an IL-13 receptor ?2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence of SEQ ID NO: 49;
a MAGE-A1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-55;
an EphA2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-68;
a p53 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:69-80;
a k-Ras antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:81-86;
an Ep-CAM antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:87-91;
a MUC1 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO:92 and SEQ ID NO:93;
a survivin antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:94-98;
an hTERT antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:99-104; and
a WT1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-109.
US Pat. No. 10,138,719

METHOD OF EXTRACTING BITUMEN FROM OIL SANDS WITH A PROPYLENE OXIDE CAPPED GLYCOL

Dow Global Technologies L...

1. A bitumen recovery process comprising a step of treating oil sands with a propylene oxide capped glycol ether, wherein:the oil sands are recovered by surface mining and transported to a treatment area for the step of treating the oil sands with the propylene oxide capped glycol ether or the oil sands are recovered by in situ production and in situ treatment occurs during the step of treating the oil sands with the propylene oxide capped glycol ether, and
the propylene oxide capped glycol ether is described by the following structure:
RO—(C2H4O)n—CH2CH(CH3)OHwherein R is a linear, branched, cyclic alkyl, phenyl, or alkyl phenyl group and n is 1 to 10.
US Pat. No. 10,137,439

PROCESS AND CATALYST FOR THE PRODUCTION OF PYRIDINE AND ALKYL DERIVATIVES THEREOF

1. A method of enhancing the catalytic activity of zinc containing zeolite-based heterogeneous catalyst for the production of pyridine and its alkyl derivatives during a base synthesis reaction, the method comprising:(1) preparing an aqueous slurry comprising components (a) a zeolite selected the group consisting of ZSM-5, ZSM-11 and combinations thereof, (b) optionally zinc, (c) a binder and (d) clay in amounts sufficient to provide an L/B ratio of about 1.5 to about 4.0 in the final catalyst composition;
(2) spray drying the slurry to provide catalyst particles having a particle size of about 40 ?m to about 200 ?m;
(3) calcining the particles to provide a final catalyst composition having an L/B ratio of about 1.5 to about 4.0.
US Pat. No. 10,137,184

SCAFFOLDS FOR CELL TRANSPLANTATION

President and Fellows of ...

1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open, interconnected macropores;a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells, B-cells, NK cells, and dendritic cells;
a tumor antigen; and
an immune response-promoting bioactive factor comprising a small molecule, wherein the GM-CSF, the tumor antigen, or the immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition.
US Pat. No. 10,138,465

DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS

Janssen Biotech, Inc., H...

1. A method for producing pancreatic endocrine cells from human pluripotent stem cells, comprising the steps of:(a) differentiating human pluripotent stem cells into foregut endoderm cells; and
(b) differentiating the foregut endoderm cells into pancreatic endocrine cells by treatment with a medium supplemented with (i) a thyroid hormone selected from triiodothyronine, thyroxine, analogues of triiodothyronine, analogues of thyroxine or mixtures thereof, or (ii) both thyroid hormone and an ALK5 inhibitor.
US Pat. No. 10,137,441

METHOD FOR PRODUCING ALUMINOSILICATE CATALYST, ALUMINOSILICATE CATALYST, AND METHOD FOR PRODUCING MONOCYCLIC AROMATIC HYDROCARBONS

1. A method for producing an aluminosilicate catalyst, comprising:a first phosphorus treatment step of treating a crystalline aluminosilicate with a first phosphorus compound, wherein the crystalline aluminosilicate comprises at least one component selected from the group consisting of medium pore zeolites and large pore zeolites as a main component,
mixing a phosphorus-treated crystalline aluminosilicate obtained in the first phosphorus treatment step with a binder, molding a mixture of the phosphorus-treated crystalline aluminosilicate and the binder to form a molded body, and then firing the molded body, and
a second phosphorus treatment step of treating the fired molded body with a second phosphorus compound.
US Pat. No. 10,138,209

PROCESS FOR PURIFYING AN IONIC LIQUID

Evonik Degussa GmbH, Ess...

1. A process for purifying an ionic liquid of the structure Q+A?, wherein Q+ is a 1,3-dialkylimidazolium ion, and wherein A? is selected from the group consisting of: dialkyl phosphate; alkyl sulphate; alkyl sulphonate; alkyl carboxylate; chloride; hydrogen sulphate; dihydrogen phosphate; monoalkyl hydrogen phosphate; and nitrate;wherein the ionic liquid of the structure Q+A? is subjected to a stripping with water vapour having a temperature of ?99° C.
US Pat. No. 10,138,466

COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO CELL POPULATIONS COMPRISING BETA-LIKE CELLS

REGENERATIVE MEDICAL SOLU...

1. A kit, comprising:differentiation medium comprising a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, nicotinamide, exendin-4, ALK5i II, and forskolin.
US Pat. No. 10,137,187

RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE

1. A method for raising an immune response in a human patient, the method comprising administering a therapeutically effect amount of an immunogenic composition to the patient, wherein the immunogenic composition comprises an effective amount of purified dengue virus envelope (“E”) protein monomers of serotype DEN-1, DEN-2, DEN-3, and DEN-4, a pharmaceutically acceptable excipient, and an effective amount of adjuvant; wherein the E proteins each constitute approximately 80% of the length of wild type E starting from amino acid residue 1 at its N-terminus, such that said E protein is secretable into growth medium when expressed recombinantly in a host cell; wherein the amount of DEN4 E protein is about 1.5 to about 3 times the individual amounts of DEN1, DEN2, and DEN3 E proteins, and wherein the composition induces the production of neutralizing antibodies in human subjects.
US Pat. No. 10,138,468

METHOD FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MULTI-COMPETENT RENAL PRECURSORS

Hoffmann-La Roche Inc., ...

1. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of:a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium,
b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), and
c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1.
US Pat. No. 10,138,471

INSERTION OF CHARGE IN THE HYDROPHOBIC INTERIOR OF PROTEINS AS A STRATEGY FOR ENGINEERING PH-SENSITIVE SWITCHES

THE JOHNS HOPKINS UNIVERS...

1. A non-naturally occurring protein comprising an artificial pH-sensitive conformational switch that responds to a change in pH, within a range of pH 5.0 to pH 9.0, by causing a cooperative unfolding transition of the protein, wherein the protein comprises two or more ionizable amino acid residues selected from Lys, Asp, and Glu, that titrate with a pKa value shifted relative to the normal pKa value in water for the one or more ionizable amino acid residues, and wherein the two or more ionizable amino acid residues comprise two or more alternative amino acid residues that have been substituted for two or more amino acid residues in an internal region of the protein.
US Pat. No. 10,138,473

THERMOSTABLE PROTEASE VARIANTS

1. A polypeptide having protease activity comprising at least 95% identity to amino acids 1 to 177 of SEQ ID NO: 2 and a substitution at position 79 using SEQ ID NO: 2 for numbering, wherein the polypeptide has improved thermostability compared to the protease shown in amino acids 1 to 177 of SEQ ID NO: 2.
US Pat. No. 10,137,193

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Sanofi Biotechnology, (F...

1. A method for treating persistent asthma in a subject in need thereof comprising administering to the subject a combination therapy comprising:i) one or more maintenance doses of an inhaled corticosteroid (ICS),
ii) one or more maintenance doses of a long-acting beta2-adrenergic agonist (LABA),
iii) a loading dose of about 600 mg of an antibody or an antigen-binding fragment thereof that specifically binds to interleukin-4 receptor (IL-4R) comprising three Heavy chain Complementarity Determining Region (HCDR) sequences comprising SEQ ID NOs: 3, 4, and 5, and three Light chain Complementarity Determining Region (LCDR) sequences comprising SEQ ID NOs: 6, 7, and 8, and
iv) one or more maintenance doses of about 300 mg of the antibody or the antigen-binding fragment thereof,
wherein the ICS and LABA are administered for the duration of administration of the antibody or the antigen-binding fragment thereof.
US Pat. No. 10,138,476

USING RNA-GUIDED FOKI NUCLEASES (RFNS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING

The General Hospital Corp...

1. A composition comprising:a nucleic acid encoding an RNA-guided FokI Nuclease (RFN) fusion protein comprising a FokI catalytic domain sequence fused to the amino terminus of a catalytically inactive Streptococcus pyogenes CRISPR-associated 9 (dCas9) protein comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 5, wherein said catalytically inactive S. pyogenes Cas9 has point mutations at amino acid residues corresponding to positions (i) D10, E762, H983, or D986, and (ii) H840 or N863 of S. pyogenes Cas9, an intervening linker from 2 to 30 amino acids; and
a nucleic acid encoding two guide RNAs that direct said RFN fusion protein to a first target genomic sequence and a second target genomic sequence, wherein the guide RNAs that direct said RFN fusion protein to said first target genomic sequence and said second target genomic sequence are spaced 10 to 20 nucleotides apart, and said first target genomic sequence comprises a PAM recognition sequence positioned upstream of said first target genomic sequence and said second target genomic sequence comprises a PAM recognition sequence positioned downstream of said second target genomic sequence.
US Pat. No. 10,137,452

THERMAL UNIFORMITY FOR THERMAL CYCLER INSTRUMENTATION USING DYNAMIC CONTROL

LIFE TECHNOLOGIES CORPORA...

1. A method for performing polymerase chain reactions (PCR), the method comprising:measuring a first temperature, by a first sensor, of a first sample block sector of a sample block;
measuring a second temperature, by a second sensor, of a second sample block sector of the sample block, wherein the second sample block sector is located adjacent to the first sample block sector;
calculating, by a controller, a difference in temperature between the first temperature and the second temperature; and
adjusting, by the controller, the first temperature of the first sample block sector based on the difference in temperature to increase thermal uniformity across the first sample block sector and the second sample block sector during a PCR thermal protocol.
US Pat. No. 10,138,477

METHOD OF PRODUCING SECRETABLE ANTIBODIES BY EXPRESSION IN SACCHAROMYCES CEREVISIAE

MERCK PATENT GmbH, Darms...

1. A method for producing a selected population of antibodies, by expression, secretion, and presentation of a mixed population of antibodies on the surface of yeast cells, the method comprising the following steps:(a) providing host cells of the yeast species Saccharomyces cerevisiae that have been transfected with a first and a second nucleic acid molecule on expression plasmids, wherein the first nucleic acid molecule comprises a yeast GAL1 promoter and encodes a fusion protein, wherein the GAL1 promoter is capable of controlling the expression of said fusion protein as a function of cultivation conditions, and wherein said fusion protein comprises an alpha-agglutinin cell surface anchor protein and an Fc binding domain, and wherein the second nucleic acid molecule encodes an antibody of said mixed population of antibodies and is under the control of a permanently active promoter;
(b) cultivating said host cells of (a) in the presence of >10% w/v polyethylene glycol (PEG) having a molecular weight of >5,000 in the cultivation medium, under conditions whereby said mixed population of antibodies is simultaneously co-expressed in soluble form with said fusion protein, whereby said fusion protein is anchored to the surface of the host cell upon secretion, and whereby each host cell expresses an individual antibody of said mixed population of antibodies, and whereby said antibodies of said mixed population of antibodies are secreted from the host cells and bound in non-covalent form to said Fc binding domain of said fusion protein on the surface of each host cell,
(c) selecting and isolating a population of said host cells of (b) according to the affinity of individual antibodies in said mixed population of antibodies by binding a detection marker to said individual antibodies, wherein the detection marker is selective for said individual antibodies, and isolating the yeast cells which are bound to the detection marker,
(d) culturing said isolated host cells of (c) and expressing said individual antibodies selected in (c) under cultivation conditions wherein little or no expression of said fusion protein occurs and wherein the expressed antibodies from said second expression step are secreted from the yeast cell without binding to the surface of said isolated host cells of (c), and
(e) isolating the secreted antibodies expressed in (d) selected binding affinity.